SCYNEXIS, Inc.
News
(3)April 2026
SCYNEXIS seeks shareholder approval for board nominees and share increases
# 📜 What This Document Is 🗳️ This document is a Preliminary Proxy Statement, which is essentially a mandatory educational guide for shareholders. It was filed by SCYNEXIS, Inc., to prepare investors for their 2026 Annual Meeting of Stockholders. 👉 The primary purpose is to tell you exactly what
March 2026
SCYNEXIS INC — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, a report companies use to announce major events to investors. In this case, SCYNEXIS is announcing it has **completed the acquisition** of a new drug candidate called PXL-770 (now named SCY-770) from a French company, Poxel S.A. It’s a press rele
SCYNEXIS INC — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing from SCYNEXIS, a biotech company. Attached is the main event: a **Securities Purchase Agreement**. Think of it as a formal IOU and rulebook for a major cash deal. The company is selling stock and warrants to a group of investors to raise money. This d
Peers in Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Company Limited
Zoetis Inc.
Haleon plc
Teva Pharmaceutical Industries Limited
United Therapeutics Corporation
Viatris Inc.
Regencell Bioscience Holdings Limited
Neurocrine Biosciences, Inc.
Elanco Animal Health Incorporated
Dr. Reddy's Laboratories Limited